Bevacizumab (bevacizumab)

Bevacizumab is approved for: Metastatic colorectal cancer (mCRC) in combination with intravenous fluorouracil-based chemotherapy, first- or second-line (not indicated for adjuvant colon cancer); First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), with carboplatin and paclitaxel; Recurrent glioblastoma (GBM) in adults; Metastatic renal cell carcinoma (mRCC) in combination with interferon alfa; Persistent, recurrent or metastatic cervical cancer, with paclitaxel plus cisplatin or paclitaxel plus topotecan. It is a bevacizumab (VEGF/VEGFR inhibitor — recombinant humanized IgG1 monoclonal antibody), originally marketed as Avastin by Genentech, Inc. / F. Hoffmann-La Roche Ltd.

Bevacizumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — the small-molecule bioequivalence concept (AUC/Cmax within 80-125%) does not apply. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural similarity testing, functional (potency) assays, a comparative pharmacokinetic study with pharmacodynamic markers, and a comparative immunogenicity assessment of anti-drug antibodies (ADA). WHO guidance and EMA require head-to-head data and state that comparison based on historical data is not acceptable; a comparative efficacy trial may be waived if biosimilarity is sufficiently established from the analytic, functional, PK and immunogenicity package, and FDA's 2025 and March 2026 draft guidances further reduce the expectation for comparative efficacy and clinical PK studies. Immunogenicity is a specific concern for this class: e.g. the ABP215 (Mvasi) programme compared ADA incidence against EU-approved bevacizumab in NSCLC and found similar rates with no apparent impact on safety, activity or PK. FDA's June 2024 draft guidance removed the expectation for switching studies to demonstrate interchangeability, and no bevacizumab product is currently FDA-approved as an interchangeable. Indian 'similar biologics' (Krabeva, Bevatas, Bryxta, Cizumab) were approved under CDSCO/Indian guidelines requiring analytical similarity, comparative PK/PD and immunogenicity data, but typically with less Phase III comparative efficacy evidence than FDA/EMA require. Note on warnings: the reference product's US boxed warning (gastrointestinal perforations, surgery and wound-healing complications, and hemorrhage) was removed by FDA in June 2019, so current US labels for Avastin and its bevacizumab biosimilars carry no boxed warning — the perforation, wound-healing and hemorrhage risks remain as Warnings and Precautions. Manufacturers supplying bevacizumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Healthcare Pharmaceuticals Ltd., Hetero, Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Abevmy, Avastin, Bevacimab, Bevaris, Bevastim, Bevixa.

Bevacizumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — the small-molecule bioequivalence concept (AUC/Cmax within 80-125%) does not apply. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural similarity testing, functional (potency) assays, a comparative pharmacokinetic study with pharmacodynamic markers, and a comparative immunogenicity assessment of anti-drug antibodies (ADA). WHO guidance and EMA require head-to-head data and state that comparison based on historical data is not acceptable; a comparative efficacy trial may be waived if biosimilarity is sufficiently established from the analytic, functional, PK and immunogenicity package, and FDA's 2025 and March 2026 draft guidances further reduce the expectation for comparative efficacy and clinical PK studies. Immunogenicity is a specific concern for this class: e.g. the ABP215 (Mvasi) programme compared ADA incidence against EU-approved bevacizumab in NSCLC and found similar rates with no apparent impact on safety, activity or PK. FDA's June 2024 draft guidance removed the expectation for switching studies to demonstrate interchangeability, and no bevacizumab product is currently FDA-approved as an interchangeable. Indian 'similar biologics' (Krabeva, Bevatas, Bryxta, Cizumab) were approved under CDSCO/Indian guidelines requiring analytical similarity, comparative PK/PD and immunogenicity data, but typically with less Phase III comparative efficacy evidence than FDA/EMA require. Note on warnings: the reference product's US boxed warning (gastrointestinal perforations, surgery and wound-healing complications, and hemorrhage) was removed by FDA in June 2019, so current US labels for Avastin and its bevacizumab biosimilars carry no boxed warning — the perforation, wound-healing and hemorrhage risks remain as Warnings and Precautions. Manufacturers supplying bevacizumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Healthcare Pharmaceuticals Ltd., Hetero, Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Abevmy, Avastin, Bevacimab, Bevaris, Bevastim, Bevixa.

Standard dosing for bevacizumab: Administered as an intravenous infusion after dilution; not a bolus. Metastatic colorectal cancer: 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks in combination with fluorouracil-based chemotherapy. First-line non-squamous NSCLC: 15 mg/kg IV every 3 weeks with carboplatin/paclitaxel. Recurrent glioblastoma: 10 mg/kg IV every 2 weeks. Metastatic renal cell carcinoma: 10 mg/kg IV every 2 weeks with interferon alfa. Cervical cancer: 15 mg/kg IV every 3 weeks. Ovarian cancer: 15 mg/kg IV every 3 weeks (10 mg/kg every 2 weeks for platinum-resistant disease with weekly chemotherapy). HCC: 15 mg/kg IV every 3 weeks after atezolizumab 1,200 mg on the same day. Dose adjustments: No dose reductions are recommended for bevacizumab; dose modifications are hold/discontinue decisions. Withhold for at least 28 days before elective surgery, and do not administer for at least 28 days after major surgery and until adequate wound healing. Discontinue for: gastrointestinal perforation (any grade), tracheoesophageal fistula (any grade), Grade 4 fistula or fistula involving any internal organ; necrotizing fasciitis; Grade 3-4 hemorrhage; severe arterial thromboembolic event; Grade 4 venous thromboembolic event; hypertensive crisis or hypertensive encephalopathy; posterior reversible encephalopathy syndrome (PRES); nephrotic syndrome; severe infusion-related r

Elimination half-life: Approximately 20 days (range 11-50 days) based on a population pharmacokinetic analysis of 491 patients receiving 1 to 20 mg/kg weekly, every 2 weeks or every 3 weeks.. Dosing intervals are designed around this, which is why most regimens are once or twice daily.

The most frequently reported side effects of bevacizumab are epistaxis (nosebleeds), headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin. Serious but less common reactions include hemorrhage (including serious/fatal bleeding), gastrointestinal perforation and fistulae, arterial and venous thromboembolic events, posterior reversible encephalopathy syndrome (pres). Routine monitoring: Blood pressure every 2 to 3 weeks during treatment (Grades 3-4 hypertension occur in 5-18% of patients); Urine protein by dipstick at serial urinalyses; perform 24-hour urine collection if dipstick is 2+ or greater; Signs of gastrointestinal perforation or fistula (abdominal pain, constipation, vomiting, fever). Report any new or worsening symptom to your treating physician — most adverse effects are managed by dose reduction rather than stopping treatment.

Recommended monitoring for bevacizumab: Blood pressure every 2 to 3 weeks during treatment (Grades 3-4 hypertension occur in 5-18% of patients); Urine protein by dipstick at serial urinalyses; perform 24-hour urine collection if dipstick is 2+ or greater; Signs of gastrointestinal perforation or fistula (abdominal pain, constipation, vomiting, fever); Bleeding and hemoptysis, including a recent history of hemoptysis of half a teaspoon or more; Wound healing status in relation to any surgery (hold 28 days before and after); Signs of arterial or venous thromboembolism; Neurologic symptoms for PRES (headache, seizure, lethargy, confusion, visual disturbance); Cardiac assessment / LVEF in patients at risk of congestive heart failure; Varices evaluation within 6 months of starting treatment in patients with hepatocellular carcinoma

Storage: Store refrigerated at 2-8°C (36-46°F); do not freeze. Keep the vial in the outer carton to protect from light. Avastin solution may be stored at 2-8°C for up to 8 hours if not used immediately; per the EU label, infusion solutions should be used immediately after dilution unless prepared in a sterile environment, in which case they are stable for 30 days at 2-8°C. Keep the product in its original packaging and check the expiry date printed on the pack.

Bevacizumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — the small-molecule bioequivalence concept (AUC/Cmax within 80-125%) does not apply. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural similarity testing, functional (potency) assays, a comparative pharmacokinetic study with pharmacodynamic markers, and a comparative immunogenicity assessment of anti-drug antibodies (ADA). WHO guidance and EMA require head-to-head data and state that comparison based on historical data is not acceptable; a comparative efficacy trial may be waived if biosimilarity is sufficiently established from the analytic, functional, PK and immunogenicity package, and FDA's 2025 and March 2026 draft guidances further reduce the expectation for comparative efficacy and clinical PK studies. Immunogenicity is a specific concern for this class: e.g. the ABP215 (Mvasi) programme compared ADA incidence against EU-approved bevacizumab in NSCLC and found similar rates with no apparent impact on safety, activity or PK. FDA's June 2024 draft guidance removed the expectation for switching studies to demonstrate interchangeability, and no bevacizumab product is currently FDA-approved as an interchangeable. Indian 'similar biologics' (Krabeva, Bevatas, Bryxta, Cizumab) were approved under CDSCO/Indian guidelines requiring analytical similarity, comparative PK/PD and immunogenicity data, but typically with less Phase III comparative efficacy evidence than FDA/EMA require. Note on warnings: the reference product's US boxed warning (gastrointestinal perforations, surgery and wound-healing complications, and hemorrhage) was removed by FDA in June 2019, so current US labels for Avastin and its bevacizumab biosimilars carry no boxed warning — the perforation, wound-healing and hemorrhage risks remain as Warnings and Precautions. Manufacturers supplying bevacizumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Healthcare Pharmaceuticals Ltd., Hetero, Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Abevmy, Avastin, Bevacimab, Bevaris, Bevastim, Bevixa.

Bangladesh unit prices for bevacizumab are not published per unit; the registry lists pack prices only. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.